Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 12, Décembre 2004
Page(s) 1104 - 1108
Section M/S revues
DOI https://doi.org/10.1051/medsci/200420121104
Publié en ligne 15 décembre 2004
  1. Larrue V, Amarenco P, Caussanel JP, et al. Recommendations for the use of intravenous thrombolytic therapy in cerebrovascular ischemic accident. French society of neurovascular disorders. Rev Neurol (Paris) 2000; 156 : 1178–85.
  2. The National institute of neurological disorders and stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 : 1581–7.
  3. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome : the NINDS rt-PA stroke study. Neurology 2000; 55 : 1649–55.
  4. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA 1995; 274 : 1017–25.
  5. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second european-australasian acute stroke study investigators. Lancet 1998; 352 : 1245–51.
  6. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study : a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999; 282 : 2019–26.
  7. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre acute stroke trial-Italy (MAST-I) group. Lancet 1995; 346 : 1509–14.
  8. Thrombolytic therapy with streptokinase in acute ischemic stroke. The multicenter acute stroke trial-Europe study group. N Engl J Med 1996; 335 : 145–50.
  9. Donnan GA, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345 : 578–9.
  10. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment : pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363 : 768–74.
  11. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997; 350 : 607–14.
  12. Molina CA, Montaner J, Abilleira S, et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001; 32 : 1079–84.
  13. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator : a secondary analysis of the European-Australasian acute stroke study (ECASS II). Stroke 2001; 32 : 438–41.
  14. Selim M, Fink JN, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator : prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002; 33 : 2047–52.
  15. Knight RA, Dereski MO, Helpern JA, et al. Magnetic resonance imaging assessment of evolving focal cerebral ischemia. Comparison with histopathology in rats. Stroke 1994; 25 : 1252–62.
  16. Miyasaka N, Nagaoka T, Kuroiwa T, et al. Histopathologic correlates of temporal diffusion changes in a rat model of cerebral hypoxia/ischemia. Am J Neuroradiol 2000; 21 : 60–6.
  17. Del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels : inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998; 65 : 1–9.
  18. Dijkhuizen RM, Asahi M, Wu O, et al. Delayed rt-PA treatment in a rat embolic stroke model : diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging. J Cereb Blood Flow Metab 2001; 21 : 964–71.
  19. Ueda T, Hatakeyama T, Kumon Y, et al. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke 1994; 25 : 298–303.
  20. Shimosegawa E, Hatazawa J, Inugami A, et al. Cerebral infarction within six hours of onset : prediction of completed infarction with technetium-99m-HMPAO SPECT. J Nucl Med 1994; 35 : 1097–103.
  21. Del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32 : 78–86.
  22. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42 : 976–82.
  23. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59 : 862–7.
  24. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study : a randomized controlled trial. Prolyse in acute cerebral thromboembolism.JAMA 1999; 282 : 2003–11.
  25. Hacke W, Warach S. Diffusion-weighted MRI as an evolving standard of care in acute stroke. Neurology 2000; 54 : 1548–9.
  26. Parsons MW, Barber PA, Chalk J, et al. Diffusion and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51 : 28–37.
  27. Kidwell CS, Saver JL, Mattiello J, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000; 47 : 462–9.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.